UCB Sa operates in the Pharmaceutical preparations sector. UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson's disease, and in the area of immunology on allergies, bone loss disorders, Crohn's disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, UCB maintains UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. UCB also has a selective presence in primary care to support specialist products that are administered by primary care physicians. As of December 31, 2010, the Company was active in over 40 countries worldwide with ten research and development centers in Europe, the United States and Japan. In our complete report available for purchase the company is compared to: Lonza Group AG, Tessenderlo Chemie S.A. and Kemira Oyj.